November 2024 has seen a variety of biotech deals take place to advance therapies across different stages in development.

Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.

Glucagon-like peptide 1 receptor agonists and fenofibrates may protect patients with type 2 diabetes against diabetic macular ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

Struggles with obesity are a longstanding issue for millions of Americans and thousands of Iowans, but recent advancements in ...

A panelist discusses how glucagon-like peptide-1 receptor (GLP-1) agonists' cardioprotective effects likely stem from multiple physiological mechanisms, including reduced inflammation, improved ...

Randomised controlled trials and real word evidence have consistently shown that GLP-1 receptor agonists are effective and ...

GLP-1 agonists substantially slowed kidney deterioration and failure, independent of diabetes status. The most extensive and ...

Mahmoud Nassar, MD, PhD, a trainee in the endocrinology, diabetes and metabolism fellowship program at the Jacobs School of Medicine and Biomedical Sciences, received several prestigious outstanding ...

A t the SupplySide West trade show held earlier this fall, products that provide dietary support for those using GLP-1 ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Despite risks related to early-stage IP and low trading volume, SKYE's promising IP and near-term catalysts justify a ...